Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSAR Combined With Immunotherapy in Advanced Hepatocellular Carcinoma
NCT07884877Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in hepatocellular carcinoma (HCC), sponsored by Samsung Medical Center. Primary endpoint: 12-Month Progression-Free Survival Rate. Started Oct 2026; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07884877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884877.